Regeneron Pharma Live Stock Price Today, Share Analysis and Chart

Name: Regeneron Pharmaceuticals, Inc.: Is Infosys Ltd. worth buying?
Item: Regeneron Pharmaceuticals, Inc.
Rating: 2.411444375
Author: Trendlyne DVM scores

Turnaround Potential

about

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet ag...

733.88 -8.04 (-1.08%)

New 52W High in past week

271.9K

XNAS Volume

XNAS 16 Jan, 2026 11:33 AM (EST)

Medium Financial Strength

44.4 / 100

Mid Valuation

42.2 / 100

Technically Moderately Bullish

61.9 / 100

Turnaround Potential These stocks have average financials and valuation, but strong momentum indicating buying interest View Similar Embed DVM

826

1Yr Price target upside is 13%

26 analysts

Regeneron Pharma Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Regeneron Pharma Live Stock Price Today, Share Analysis and Chart

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet ag...

New 52W High in past week

SWOT Analysis

Regeneron Pharma Live Price Chart